Panelists discuss how patients with immunoglobulin A (IgA) nephropathy typically present with microscopic or gross hematuria, often during upper respiratory infections, along with variable proteinuria ...

Immunoglobulin A (IgA) nephropathy is a condition that causes a certain type of protein to build up in your kidneys. It progresses differently in everyone. Your kidneys might still work well years ...

Edgar Lerma, MD, provides insights into the pathophysiology of IgA nephropathy (IgAN) and the therapeutic promise of targeting APRIL.

The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...

Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...

The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...

For Andrew Schukraft, the doctor's appointment was just a routine sports physical exam. After all, the 16-year-old was in seemingly good health. But when he went in for the exam, the now 26-year-old's ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an Outperform rating ...